The latest announcement is out from Akari Therapeutics (AKTX).
On May 1, 2024, the Company publicized the successful completion of a strategic pipeline review and prioritization of programs following its merger agreement with Peak Bio Inc. The announcement highlights the advancement and refinement of the combined entity’s initiatives, signaling potential growth and investment opportunities to those watching the biotech sector.
For a thorough assessment of AKTX stock, go to TipRanks’ Stock Analysis page.
